- Title
- Targeting MicroRNA function in respiratory diseases: mini-review
- Creator
- Maltby, Steven; Plank, Maximillian; Tay, Hock L.; Collison, Adam; Foster, Paul S.
- Relation
- Frontiers in Physiology Vol. 7, Issue February 2016, no. 21
- Publisher Link
- http://dx.doi.org/10.3389/fphys.2016.00021
- Publisher
- Frontiers Research Foundation
- Resource Type
- journal article
- Date
- 2016
- Description
- MicroRNAs (miRNAs) are small non-coding RNA molecules that modulate expression of the majority of genes by inhibiting protein translation. Growing literature has identified functional roles for miRNAs across a broad range of biological processes. As such, miRNAs are recognized as potential disease biomarkers and novel targets for therapies. While several miRNA-targeted therapies are currently in clinical trials (e.g., for the treatment of hepatitis C virus infection and cancer), no therapies have targeted miRNAs in respiratory diseases in the clinic. In this mini-review, we review the current knowledge on miRNA expression and function in respiratory diseases, intervention strategies to target miRNA function, and considerations specific to respiratory diseases. Altered miRNA expression profiles have been reported in a number of respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. These include alterations in isolated lung tissue, as well as sputum, bronchoalveolar lavage fluids and peripheral blood or serum. The observed alterations in easily accessible body fluids (e.g., serum) have been proposed as new biomarkers that may inform disease diagnosis and patient management. In a subset of studies, miRNA-targeted interventions also improved disease outcomes, indicating functional roles for altered miRNA expression in disease pathogenesis. In fact, direct administration of miRNA-targeting molecules to the lung has yielded promising results in a number of animal models. The ability to directly administer compounds to the lung holds considerable promise and may limit potential off-target effects and side effects caused by the systemic administration required to treat other diseases.
- Subject
- microRNA; respiratory diseases; non-coding RNA; antagomir; mimic
- Identifier
- http://hdl.handle.net/1959.13/1344227
- Identifier
- uon:29352
- Identifier
- ISSN:1664-042X
- Rights
- © 2016 Maltby, Plank, Tay, Collison and Foster. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Language
- eng
- Full Text
- Reviewed
- Hits: 2096
- Visitors: 2431
- Downloads: 371
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 658 KB | Adobe Acrobat PDF | View Details Download |